In general, these results might suggest that the combination of ConvitVax and anti-PD-1 (G4) does not significantly potentiate the tumor elimination promoted by the vaccine, and has a lower ability to control tumor cells division under the treatment schedule implemented, in comparison with the vaccine treatment itself. This evidence concerns the gene PDCD1 and neoplasm.